Review
Oncology
Khadijeh Barzaman, Rana Vafaei, Mitra Samadi, Mohammad Hossein Kazemi, Aysooda Hosseinzadeh, Parnaz Merikhian, Shima Moradi-Kalbolandi, Mohammad Reza Eisavand, Houra Dinvari, Leila Farahmand
Summary: Tumors use various pathways to evade the immune system, which can be bypassed through alternative routes. Key molecules such as MET, HGF, and EpCAM, which are overexpressed in some cancers, share intracellular signaling pathways. Simultaneous targeting of these molecules can help inhibit substitute pathways that tumors use to evade the immune system and develop resistance to therapy.
CANCER CELL INTERNATIONAL
(2022)
Article
Medical Laboratory Technology
Xin Yang, Hai-Yang Liao, Hai-Hong Zhang
Summary: The MET gene plays a significant role in the initiation and development of various human cancers, affecting cell proliferation, migration, and invasion. MET serves as a biomarker for diagnosis and prognosis, and is also a potential therapeutic target. Inhibiting MET expression and function may have clinical benefits in cancer treatment.
CLINICA CHIMICA ACTA
(2022)
Article
Oncology
Makoto Nishio, Terufumi Kato, Ryo Toyozawa, Toyoaki Hida
Summary: MET inhibitors used in the treatment of non-small cell lung cancer may cause peripheral edema, with potential mechanisms including disruption of vascular endothelial permeability balance and effects on renal function. Thorough assessment is needed to determine the underlying cause of edema, as it is common in cancer patients and may have similar symptoms to other conditions. Patients should be informed about the possibility of developing peripheral edema and evaluated before treatment initiation. Management options for edema include compression stockings, specific exercises, massage, limb elevation, and/or diuretic treatment.
Article
Cell Biology
Katia De Marco, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Giovanna Forte, Vittoria Disciglio, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone
Summary: Gastric cancer is the third most deadly cancer worldwide. This study identifies SMYD3 as a molecular partner of MET in gastric cancer cells and suggests that inhibiting SMYD3 could affect the HGF/MET signaling pathway. The research also demonstrates that combining SMYD3 inhibitors with MET inhibitors enhances the targeting of the HGF/MET pathway, providing a promising therapeutic target for gastric cancer treatment.
Article
Oncology
Alexander Ries, Daniela Flehberger, Astrid Slany, Christine Pirker, Johanna C. C. Mader, Thomas Mohr, Karin Schelch, Katharina Sinn, Berta Mosleh, Mir Alireza Hoda, Balazs Dome, Helmut Dolznig, Georg Krupitza, Leonhard Muellauer, Christopher Gerner, Walter Berger, Michael Grusch
Summary: This study characterizes patient-derived Meso-CAFs for the first time and demonstrates the significant impact of Meso-CAFs on PM cell growth and migration, two key characteristics of PM aggressiveness, indicating a major role of Meso-CAFs in driving PM progression. Moreover, signaling pathways required for Meso-CAF-mediated growth stimulation are identified, which could be relevant for novel therapeutic strategies against PM.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano
Summary: Entrectinib is effective in treating solid tumors with NTRK and ROS1 gene rearrangement, but its efficacy is limited by tolerance and acquired resistance. The study found that growth factors in the tumor microenvironment, such as HGF, may induce resistance to Entrectinib, but co-administering inhibitors of these factors may enhance its therapeutic efficacy.
Review
Medicine, General & Internal
Hyun Jung Kim
Summary: This review explains the role of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumorigenesis and metastasis of ovarian cancer. Clinical studies have shown promising results using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, including ovarian cancer. Combining HGF/c-MET targeted therapy with chemotherapy drugs could be an effective strategy for treating ovarian cancer.
MEDICINA-LITHUANIA
(2022)
Review
Pharmacology & Pharmacy
Jason M. Roe, Kevin Seely, Caleb J. Bussard, Emily Eischen Martin, Elizabeth G. Mouw, Kenneth W. Bayles, Michael A. Hollingsworth, Amanda E. Brooks, Kaitlin M. Dailey
Summary: Oncolytic bacteria are a type of bacteria that can specifically target tumors and stimulate immune responses. Through techniques like genetic engineering, these bacteria can be modified to enhance their ability to kill tumor cells, which is particularly useful for tumors that are difficult to access or have spread at an early stage. This review examines the interactions between oncolytic bacteria and the immune system, and discusses the potential of using these bacteria as cancer therapeutics. The review also discusses the progress of oncolytic bacteria in clinical trials and highlights the characteristics of bacteria that have shown promising results.
Review
Oncology
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi
Summary: MET receptor is a promising therapeutic target in various human cancers, with HGF/MET combination therapies showing potential in overcoming drug resistance, targeting tumor microenvironment, and modulating drug metabolism. Further research is needed to fully understand the molecular mechanisms underlying successful pharmacological combinations.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Yang Zhao, Wenling Ye, Yan-Dong Wang, Wei-Dong Chen
Summary: Hepatocyte growth factor (HGF) is a multifunctional cytokine that regulates cell growth, proliferation, and survival by activating the c-Met signaling pathway, and it plays a crucial role in liver regeneration.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Cristina Chiriaco, Chiara Donini, Marco Cortese, Stefano Ughetto, Chiara Modica, Ilaria Martinelli, Alessia Proment, Letizia Vitali, Lara Fontani, Monica Casucci, Paolo Maria Comoglio, Silvia Giordano, Dario Sangiolo, Valeria Leuci, Elisa Vigna
Summary: The study proposes an immunotherapy strategy using CAR-T lymphocytes targeting MET overexpressing tumors across different histotypes, showing specific cytotoxic activity and potential to overcome acquired resistance to MET targeting agents in cancer cells. The approach holds promise for cancers not responsive to traditional MET inhibition therapies.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Biology
Griselda Awanis, Salonee Banerjee, Robert Johnson, Sathuwarman Raveenthiraraj, Aya Elmeligy, Derek Warren, Jelena Gavrilovic, Anastasia Sobolewski
Summary: Tunneling nanotubes (TNTs) play a crucial role in intercellular communication and tumor progression. This study investigates the molecular mechanisms underlying TNT formation and identifies potential targets for inhibiting TNT formation as a novel approach for cancer treatment.
LIFE SCIENCE ALLIANCE
(2023)
Article
Oncology
Chiara Modica, Marco Cortese, Francesca Bersani, Andrea Maria Lombardi, Francesca Napoli, Luisella Righi, Riccardo Taulli, Cristina Basilico, Elisa Vigna
Summary: The MET receptor and its ligand Hepatocyte Growth Factor (HGF) play important roles in cell proliferation, survival, motility, and invasion. The HGF/MET axis regulates both cell-autonomous and non-cell-autonomous functions in cancer cell dissemination. Knocking out the MET gene in cancer cells allowed for the evaluation of the role of the HGF/MET axis in cell-autonomous functions independently of its effect on tumor microenvironment cells. The results suggest a crucial contribution of the HGF/MET axis in driving the metastatic process.
Review
Biochemistry & Molecular Biology
Rishav Sharma, Rishabha Malviya
Summary: Pancreatic cancer is highly lethal and difficult to treat, with hypoxia promoting its development and spread. The interaction between cancer cells, stromal cells, and pancreatic stellate cells mediated by the HGF/c-MET pathway plays a crucial role in disease progression. Hypoxia and HGF/c-MET expression are important factors in pancreatic cancer treatment.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Article
Oncology
Baiyao Wang, Wei Liu, Chunshan Liu, Kunpeng Du, Zhaoze Guo, Guoqian Zhang, Zhong Huang, Shuhui Lin, Bohong Cen, Yunhong Tian, Yawei Yuan, Junguo Bu
Summary: This study investigated the role of cancer-associated fibroblasts (CAFs) in the radiosensitivity of breast cancer cells. The researchers found that CAFs secrete HGF to activate the c-Met signaling pathway, promoting epithelial-to-mesenchymal transition, growth, and radioresistance of breast cancer cells. Radiation was also observed to enhance HGF secretion by CAFs and increase c-Met expression in breast cancer cells, leading to the activation of the HGF/c-Met signaling pathway.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
